Go to content oder Go to navigation


Andrea Henrich
Pharmacist / Freie Universität Berlin

Begin: August 2013 - End: December 2017
Supervisor: Prof. Charlotte Kloft
Co-Supervisor: Prof. Wilhelm Huisinga
Mentor: Boehringer Ingelheim

PhD Project

Pharmacometric modelling and simulation to optimise paclitaxel combination therapy based on pharmacokinetics, cumulative neutropenia and efficacy (PhD thesis)

Scientific interests

Anticancer drugs are often associated with myelotoxicity, in particular reduction of neutrophils (neutropenia) which is one of the most important dose-limiting adverse events in many anticancer treatment options. Especially patients receiving high-dose chemotherapy exhibit severe neutropenia. The major fatal complication of acute neutropenia is the occurrence of severe infections which are quantitatively related to the degree and the duration of neutropenia.

Hence, mechanism-based models that can describe and predict both the degree and the duration of neutropenia as haematological toxicity are of particular interest.

Mechanistic pharmacokinetic/pharmacodynamic (PK/PD) models describe the maturation of haematopoietic cells under the impact of myelotoxic drugs in patients. These models are built in order to combine the pharmacokinetic profiles of chemotherapeutic drugs and the time course of the resulting neutropenia.

Simulations should help to explore the contribution of the single drugs of anti-cancer regimens to myelosuppression and to to investigate the benefit of peripheral blood stem cell retransfusion (PBSCT) and granulocyte-colony stimulating factor G-CSF administration as a stem cell rescue to circumvent this adverse event in particular.

As semi-mechanistic models make it possible to differentiate between system-related and drug-specific parameters, goal of my PhD thesis is to explore drug-related parameters for their use in PK/PD modelling and prediction of neutropenia. In combination with efficacy, these models shall contribute to evaluate clinical benefit/risk ratios in the management of cancer patients.


  • A. Henrich, C. Kloft.
    Damit nicht mehr alles grau erscheint - Wichtiges in der Behandlung von Depressionen.
    Lange Nacht der Wissenschaften, Berlin, Germany, 10 May 2014.
  • A. Henrich, Z. Parra-Guillen, C. Kloft.
    Comparison of three PK/PD models for describing neutropenia in cancer patients treated with topotecan.
    Annual Meeting of the Central European Society of Anticancer Research (CESAR), Bonn, Germany, 26-28 June 2014.
    Abstractbook, 42, (2014).
  • A. Henrich, Z. Parra-Guillen, C. Kloft.
    Comparison of three pharmacokinetic/toxicity models describing neutropenia caused by topotecan in cancer patients.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 136, (2014).


  • 08/2013: Graduate Research Training Program ‘Pharmacometrics & Computational Disease Modeling’ at the Freie Universität Berlin
  • 07/2013: Registration as pharmacist

  • 11/2012-04/2013: Preregistration student at Alte Apotheke (public pharmacy) in Garmisch-Partenkirchen

  • 05/2012-10/2012: Preregistration student at Boehringer Ingelheim, production of solid dosage forms

  • 09/2011-12/2011: King’s College London; ERASMUS Scholarship; Postgraduate Taught

  • 2007-2012: Studies of Pharmacy at J. W. Goethe-University, Frankfurt